HIV-1-infected patients in Uganda and Zimbabwe with high baseline viral load and advanced diseases were treated with zidovudine, lamivudine and tenofovir. The combination of drugs maintained good antiviral efficacy over a period of 48 weeks; the proportion of cases showing signs of resistance increased over time, but no pateints had to be switched to second-line treatment.
Kaleebu, P. 48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial. Presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24-27 July 2005. (2006)